このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) (AMARONE)

2026年10月9日 更新者:EyeBiotech Ltd.

A 2-part Study Consisting of an Open-label Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Single-masked Comparative Safety and Preliminary Efficacy Study of Intravitreal (IVT) Remigromig in a Mixed Population of Participants With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)

EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig (EYE103) in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.

In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of remigromig will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study.

In the second part of the study, called the dose finding part two doses of remigromig will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.

調査の概要

詳細な説明

EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.

In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of remigromig will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study.

In the second part of the study, called the dose finding part two doses of remigromig will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.

研究の種類

介入

入学 (実際)

33

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Arizona
      • Phoenix、Arizona、アメリカ、85032
        • Phoenix, AZ
    • California
      • Bakersfield、California、アメリカ、93309
        • Bakersfield, CA
      • Modesto、California、アメリカ、95356
        • Modesto, CA
      • Mountain View、California、アメリカ、94040
        • Mountain View, CA
      • Sacramento、California、アメリカ、95825
        • Sacramento, CA
      • Sacramento、California、アメリカ、95841
        • Sacramento, CA
    • Colorado
      • Colorado Springs、Colorado、アメリカ、80909
        • Colorado Springs, Colorado
      • Lakewood、Colorado、アメリカ、80288
        • Lakewood, CO
    • Florida
      • Pompano Beach、Florida、アメリカ、33064
        • Pompano Beach
    • Illinois
      • Lemont、Illinois、アメリカ、60439
        • Lemont, NV
    • Maryland
      • Hagerstown、Maryland、アメリカ、21740
        • Hagerstown, MD
    • Nevada
      • Reno、Nevada、アメリカ、89502
        • Reno, NV
    • South Carolina
      • West Columbia、South Carolina、アメリカ、29169
        • West Columbia, SC
    • Tennessee
      • Germantown、Tennessee、アメリカ、38138
        • Germantown, TN
      • Knoxville、Tennessee、アメリカ、37922
        • Knoxville, TN
      • Nashville、Tennessee、アメリカ、37203
        • Nashville, TN
    • Texas
      • Abilene、Texas、アメリカ、79606
        • Abilene, TX
      • Amarillo、Texas、アメリカ、79109
        • Amarillo, TX
      • Austin、Texas、アメリカ、78705
        • Austin, TX
      • Bellaire、Texas、アメリカ、77401
        • Bellaire, TX
      • Dallas、Texas、アメリカ、75231
        • Dallas, TX
      • Katy、Texas、アメリカ、77494
        • Katy, TX
      • McAllen、Texas、アメリカ、78503
        • McAllen, TX
      • Plano、Texas、アメリカ、75075
        • Plano, TX
      • Round Rock、Texas、アメリカ、78681
        • Round Rock, TX
      • San Antonio、Texas、アメリカ、78240
        • San Antonio, TX
      • The Woodlands、Texas、アメリカ、77384
        • The Woodlands, TX
      • Caba、アルゼンチン、1023
        • Caba, Argentina
    • Buenos Aires
      • Ciudad Autonoma de Buenos Aires、Buenos Aires、アルゼンチン、C1121ABB
        • Ciudad Autonoma Buenos Aires
      • London、イギリス、W1G7LB
        • London, UK
    • England
      • London、England、イギリス、NW10 7NS
        • London, England
    • PR
      • Arecibo、PR、プエルトリコ、00612
        • Arecibo, PR

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

50年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
  • DME patients must be ≥ 18 years of age, NVAMD patients must be ≥ 50 years of age
  • Diagnosis of either DME or NVAMD. DME patients must be treatment naïve. NVAMD patients can be either treatment naïve or treatment experienced.
  • DME patients must have vision loss in the study eye
  • NVAMD patients can be either treatment-naïve or treatment experienced with vision loss in the study eye

Exclusion Criteria:

  • Be pregnant or breastfeeding
  • History of cataract surgery and/or minimally invasive glaucoma surgery (MIGS) within 3 months of Screening
  • Yttrium-Aluminum Garnet (YAG) laser capsulotomy within 2 months of Screening
  • Any other condition except for DME or NVAMD or that could affect interpretation of study assessments

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:順次割り当て
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Dose 1

Part 1 MAD Portion Dose 1 - Low Dose

Remigromig is a humanized antibody formulated for IVT administration

他の名前:
  • EYE103
実験的:Dose 2

Part 1 MAD Portion Dose 2 - Low-Mid Dose

Remigromig is a humanized antibody formulated for IVT administration

他の名前:
  • EYE103
実験的:Dose 3

Part 1 MAD Portion Dose 3 - Mid-High Dose

Remigromig is a humanized antibody formulated for IVT administration

他の名前:
  • EYE103
実験的:Dose 4

Part 1 MAD Portion Dose 4 - High Dose

Remigromig is a humanized antibody formulated for IVT administration

他の名前:
  • EYE103
実験的:DME Medium Dose

Part 2 Naïve DME monotherapy Medium Dose

Remigromig is a humanized antibody formulated for IVT administration

他の名前:
  • EYE103
実験的:DME High Dose

Part 2 Naïve DME monotherapy High Dose

Remigromig is a humanized antibody formulated for IVT administration

他の名前:
  • EYE103
実験的:Naïve NVAMD Medium Dose

Part 2 Naïve NVAMD combination therapy Medium Dose

Remigromig is a humanized antibody formulated for IVT administration

他の名前:
  • EYE103
実験的:Naïve NVAMD High Dose

Part 2 Naïve NVAMD combination therapy High Dose

Remigromig is a humanized antibody formulated for IVT administration

他の名前:
  • EYE103
実験的:Experienced NVAMD Medium Dose

Part 2 Experienced NVAMD combination therapy Medium Dose

Remigromig is a humanized antibody formulated for IVT administration

他の名前:
  • EYE103
実験的:Experienced NVAMD High Dose

Part 2 Experienced NVAMD combination therapy High Dose

Remigromig is a humanized antibody formulated for IVT administration

他の名前:
  • EYE103

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)
時間枠:Up to approximately 12 weeks

Systemic DLTs are defined as a Grade III (severe), IV (life threatening) or V (death related to adverse event) toxicities as defined in the National Cancer Institute (NCI) Common Toxicity Criteria, or any significant severe toxicity deemed related to study drug by the principal investigator. Ocular DLTs are defined as: loss of 4 or more lines of visual acuity, clinically significant inflammation, increase of intra-ocular pressure (IOP) from baseline of > or =15 mmHg, accelerated formation of cataract, other severe ocular abnormalities not usually seen in subjects with the condition under study, or significant retinal or choroidal vascular abnormalities seen on fluorescein angiogram deemed related to study drug by the investigator.

Up to approximately 12 weeks
Number of Participants Who Experienced an Adverse Event (AE)
時間枠:Up to approximately 12 weeks

An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

Up to approximately 12 weeks
Number of Participants Who Experienced a Serious Adverse Event (SAE)
時間枠:Up to approximately 24 weeks

An SAE is defined as any adverse experience occurring at any dose that results in any of the following outcomes: Results in death; Is life threatening (immediate risk of death); results in persistent or significant disability/incapacity; requires participant hospitalization or prolongs participant hospitalization; or results in a congenital anomaly/birth defect in a neonate/infant

Up to approximately 24 weeks
Number of Participants Who Experienced Clinically Meaningful Changes in Laboratory Assessments
時間枠:Baseline and Week 12

Clinical laboratory tests, including overnight fasting serum chemistry, lipid panel, hematology, and coagulation panel were collected at baseline and at week 12 study visit. Any laboratory test result considered by the investigator to be clinically significant was considered to be an AE. Clinically significant abnormal values were followed up until repeat test results return to normal, stabilize, or are no longer clinically significant.

Baseline and Week 12
Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) to Week 12 in the Study Eye - DME Participants
時間枠:Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 12 is presented.

Baseline and Week 12
Mean Change From Baseline in BCVA to Week 12 in the Study Eye -NVAMD Participants
時間枠:Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 12 is presented.

Baseline and Week 12

二次結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants With ETDRS BCVA Response- Treatment-Naive DME Participants
時間枠:Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who gained 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Baseline and Week 12
Number of Participants With ETDRS BCVA Response- Treatment-Naive NVAMD Participants
時間枠:Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who gained 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Baseline and Week 12
Mean Change in Retinal Central Subfield Thickness (CST) From Baseline in the Study Eye on Spectral Domain Optical Coherence Tomography (SDOCT): Treatment-naive DME Participants
時間枠:Baseline and 12 weeks

SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. A negative change (decrease) in retinal CST from baseline indicates a decrease in retinal thickness or swelling and is considered a better outcome than no change or an increase in CST. The mean change at 12 weeks in the study eye for retinal CST from baseline is presented.

Baseline and 12 weeks
Mean Change in Retinal CST From Baseline in the Study Eye on SDOCT: Treatment-naive NVAMD Participants
時間枠:Baseline and 12 weeks

SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. A negative change (decrease) in retinal CST from baseline indicates a decrease in retinal thickness or swelling and is considered a better outcome than no change or an increase in CST. The mean change at 12 weeks in the study eye for retinal CST from baseline is presented.

Baseline and 12 weeks
Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive DME Participants
時間枠:Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who lost 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Baseline and Week 12
Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive NVAMD Participants
時間枠:Baseline and Week 12

Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who lost 15 or more letters as measured by ETDRS from baseline in the study eye is presented.

Baseline and Week 12
Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive DME Participants
時間枠:Baseline and Week 12

Retinal fluid in the study eye was measured by central subfield thickness (CST) as evaluated on SDOCT. SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. This outcome measure evaluates the relative change in excess CST above > 300 um from baseline to Week 12, expressed as a percentage of the baseline value. The percent change from baseline in CST in the study eye is calculated as follows: (Excess CST Baseline-Excess CST Week 12/Excess CST Baseline) *100. Positive values represent a percent reduction in excess retinal fluid (clinical improvement), and negative values represent a percent increase in excess retinal fluid (clinical worsening).

Baseline and Week 12
Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive NVAMD Participants
時間枠:Baseline and Week 12

Retinal fluid in the study eye was measured by central subfield thickness (CST) as evaluated on SDOCT. SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. This outcome measure evaluates the relative change in excess CST above > 300 um from baseline to Week 12, expressed as a percentage of the baseline value. The percent change from baseline in CST in the study eye is calculated as follows: (Excess CST Baseline-Excess CST Week 12/Excess CST Baseline) *100. Positive values represent a percent reduction in excess retinal fluid (clinical improvement), and negative values represent a percent increase in excess retinal fluid (clinical worsening).

Baseline and Week 12

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2023年6月12日

一次修了 (実際)

2024年8月26日

研究の完了 (実際)

2024年8月26日

試験登録日

最初に提出

2023年6月14日

QC基準を満たした最初の提出物

2023年6月14日

最初の投稿 (実際)

2023年6月26日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月3日

QC基準を満たした最後の更新が送信されました

2026年10月9日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • EYE103-101
  • MK-3000-003 (その他の識別子:Merck)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する